Equillium, Inc. (NASDAQ: EQ) is now covered by analysts at Jonestrading. They set a "buy" rating on the stock.
Equillium, Inc. (EQ)
Last equillium, inc. earnings: 3/26 04:07 pm
Check Earnings Report
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
EQ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EQ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EQ alerts
High impacting Equillium, Inc. news events
Weekly update
A roundup of the hottest topics
EQ
News
- Equillium, Inc. (NASDAQ: EQ) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $3.00.MarketBeat
- Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host DiseaseBusiness Wire
- Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical HighlightsBusiness Wire
- Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis [Yahoo! Finance]Yahoo! Finance
- Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative ColitisBusiness Wire
EQ
Earnings
- 3/27/25 - Beat
EQ
Sec Filings
- 3/28/25 - Form PRE
- 3/27/25 - Form 10-K
- 3/27/25 - Form 8-K
- EQ's page on the SEC website